Effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections

Patent metadata

Field	Value
Publication number	US-9492377-B2
Application number	US-201213982255-A
Country	US
Kind code	B2
Filing date	Jan 24, 2012
Priority date	Jan 28, 2011
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

The present invention relates to an effervescent composition in solid form for use in vaginal applications for the treatment of vaginal infections.

First claim

The invention claimed is:

1. A method for treatment of a vaginal infection in a subject, the method comprising
administering to the subject an effective amount of an effervescent composition in solid form comprising:
an acid-base system comprising an organic acid and a salt of carbonate and/or bicarbonate anion; said salt being present in an amount comprised from 1 to 15% by weight, relative to the total weight of the composition,
a mixture comprising microcrystalline cellulose and arabinogalactan in a ratio by weight from 1:1 to 3:1,
at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising: Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli, Herpes simplex and Haemophilus ducreyi

the administering performed to treat the vaginal infection.

2. The method in accordance with claim 1 , wherein said composition is in the form of a tablet, ovule, lozenge or granules.

3. The method according to claim 1 wherein the organic acid is selected from the group consisting of citric acid, malic acid, tartaric acid, fumaric acid, lactic acid and mixtures thereof.

4. The method according to claim 1 wherein the salt of the carbonate and/or bicarbonate anion is selected from the group consisting of: sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, sodium glycine carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate, sodium lactate, potassium lactate, carbonate lactate and mixtures thereof.

5. The method according to claim 1 , wherein the salt of carbonate and/or bicarbonate anion is present in an amount comprised from 3 to 13% by weight, relative to the total weight of the composition.

6. The method according to claim 1 , wherein the acid-base system consists of sodium bicarbonate and citric acid, and wherein the sodium bicarbonate is present in an amount comprised from 3 to 13% by weight, relative to the total weight of the composition.

7. The method according to claim 1 , wherein said at least one probiotic bacterial strain belongs to at least one species selected from the group consisting of: Lactobacillus plantarum, Lactobacillus pentosus, Lactobacillus casei, Lactobacillus casei ssp. paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus delbrueckii, Lactobacillus delbrueckii ssp. bulgaricus, Lactobacillus delbrueckii ssp. delbrueckii, Lactobacillus fermentum, Lactobacillus gasseri, Lactobacillus reuteri, Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium animalis ssp. lactis, Bifidobacterium adolescentis, Bifidobacterium pseudocatenulatum, Bifidobacterium catenulatum or Bifidobacterium infantis ; said at least one bacterial strain is preferably selected from among: Lactobacillus salivarius CRL 1328, Lactobacillus paracasei CRL 1289, Lactobacillus gasseri CRL 1259, Lactobacillus crispatus CRL 1251, Lactobacillus crispatus CRL 1266, Lactobacillus acidophilus CRL 1294, Lactobacillus paracasei LPC 00, Lactobacillus plantarum LP 02 and Lactobacillus fermentum LF 10.

8. The method according to claim 1 , wherein the vaginal infection is vaginitis, vaginosis, candidiasis, gonorrhoea, herpes and venereal ulcer.

9. A method to treat a vaginal infection in a subject, the method comprising
administering to the subject an effective amount of an effervescent tablet in solid form comprising:
an acid-base system comprising sodium bicarbonate and citric acid; said bicarbonate being present in an amount comprised from 1 to 15% by weight, relative to the total weight of the composition,
a mixture comprising microcrystalline cellulose and arabinogalactan in a ratio by weight from 1:1 to 3:1,
at least one probiotic bacterial strain having the ability to reduce and/or eliminate the presence of pathogenic agents selected from the group comprising: Candida albicans, Candida glabrata, Candida parapsilosis, Candida krusei, Candida tropicalis, Gardnerella vaginalis, Trichomonas vaginalis, Neisseria gonorrhoeae, Escherichia coli, Herpes simplex and Haemophilus ducreyi,

the administering performed to treat the vaginal infection.

10. The method according to claim 1 , wherein the salt of the carbonate and/or bicarbonate anion is present in an amount comprised from 4 to 12% by weight, relative to the total weight of the composition.

11. The method according to claim 1 , wherein the salt of the carbonate and/or bicarbonate anion is present in an amount comprised from 5 to 10% by weight, relative to the total weight of the composition.

12. The method according to claim 1 , wherein the acid-base system consists of sodium bicarbonate and citric acid.

13. The method according to claim 12 , wherein the sodium bicarbonate is present in an amount from 5 to 10% by weight, relative to the total weight of the composition.

14. The method according to claim 3 , wherein the organic acid is citric acid.

15. The method according to claim 4 , wherein the salt of the carbonate and/or bicarbonate anion is a salt of the bicarbonate anion.

16. The method according to claim 12 , wherein the sodium bicarbonate is present in an amount from 4 to 12% by weight, relative to the total weight of the composition.

Assignees

• Mogna Giovanni
• Strozzi Gian Paolo
• Mogna Luca
• Probiotical Spa

Inventors

• Mogna Giovanni
• Strozzi Gian Paolo
• Mogna Luca

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P31/10

  Antimycotics · CPC title

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title

• A61P31/22

  for herpes viruses · CPC title

• A61P15/02

  for disorders of the vagina · CPC title